INSIGHTS
-
Why We Struggle to Find Words as We Age – New Study Explains the Science Behind “Tip-of-the-Tongue” Moments
If you’ve ever paused mid-sentence trying to remember a word that’s “right there,” you’re not alone. Word-finding difficulty – those frustrating “tip-of-the-tongue” moments – becomes more common as we age. A new study published in Aging, Neuropsychology, and Cognition by researchers at the University of Toronto and Baycrest Hospital sheds light on why this happens
-
Nearly 1 in 10 Young Adults in the U.S. Struggle With Memory and Focus, University of Utah Study Finds
A new study from the University of Utah has uncovered a troubling trend among younger Americans: nearly one in ten adults under 40 now report serious difficulty with memory, concentration, or decision-making. The findings suggest that cognitive challenges – once considered a normal part of aging – are increasingly affecting people in their 20s and
-
Microplastics Found in Human Brain Tissue – 5x Higher in Dementia Patients, UNM Study Reveals
Tiny fragments of plastic are everywhere – in the air we breathe, the water we drink, and the food we eat. But a groundbreaking study led by University of New Mexico toxicology professor Matthew Campen has found something far more alarming: microplastics are accumulating inside the human brain, and levels are five times higher in
-
Popular Vitamin B3 Supplements May Help Cancer Cells Survive, Scientists Warn
Vitamin B3 supplements have become a staple in the wellness world. Marketed for boosting energy, supporting healthy aging, and improving metabolism, products like nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), and nicotinamide (NAM) are widely available and often taken daily. But new research suggests these popular supplements may have a darker side – especially for people
-
The Lyme Disease Vaccine guide: What to Know, What’s Coming, and What It Means for You
Lyme disease has become a growing concern across much of the United States, especially in the Northeast, Midwest, and parts of the West Coast. Each year, hundreds of thousands of people are diagnosed or treated for Lyme disease, a bacterial infection spread by blacklegged ticks. For decades, prevention has relied almost entirely on avoiding tick
-
FDA Flags Serious Liver Injury Linked to Tavneos (Avacopan)
Tavneos (avacopan) is a prescription medication approved in 2021 to help treat severe active anti‑neutrophil cytoplasmic autoantibody (ANCA)‑associated vasculitis, a rare autoimmune disease that causes inflammation of small blood vessels. For many patients, Tavneos offered a new option to control a difficult and potentially life‑threatening condition. Now, the U.S. Food and Drug Administration (FDA) says
-
Long‑Term Chlorpyrifos Exposure Raises Parkinson’s Risk – What Residents Near Farms Should Know
Researchers found that people who lived or worked near sustained chlorpyrifos use had over 2.5 times the risk of developing Parkinson’s disease compared with those with little or no exposure. Lab work in mice and zebrafish also showed movement problems, loss of dopamine neurons, brain inflammation, and buildup of alpha‑synuclein – the same hallmarks seen
-
New FDA Warning: Carbidopa & Levodopa Can Cause Vitamin B6 Deficiency and Seizures – What Patients Need to Know
The FDA has told drug makers to add a warning to all products containing carbidopa & levodopa – the most common medicines for Parkinson’s symptoms – because these drugs can lower vitamin B6 (pyridoxine) and have been linked to vitamin B6 deficiency–associated seizures. The agency reviewed reports and asked manufacturers to update prescribing information so
-
Icotyde – a new psoriasis treatment pill
The U.S. Food and Drug Administration has approved Icotyde (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis in adults and in adolescents 12 years and older who weigh at least 40 kg. This is notable because Icotyde is an oral, once-daily medication that targets the IL‑23 receptor, a key part of the immune pathway that
-
BIMZELX vs SKYRIZI – one stands out in a head‑to‑head trial
A new head‑to‑head study found that bimekizumab (brand name BIMZELX) produced better short‑term joint improvement than risankizumab (brand name SKYRIZI) in adults with active psoriatic arthritis (PsA). The trial’s primary measure was ACR50 – a commonly used, fairly strict standard that means a patient has achieved at least a 50% improvement in joint signs and